%0 Journal Article %1 Levitan2011 %A Levitan, B %D 2011 %J Clinical pharmacology and therapeutics %K AntipsychoticAgents AntipsychoticAgents:adverseeffects AntipsychoticAgents:therapeuticuse Clinical Clinical:methods Clinical:trends Computer-Assisted ComputerGraphics DataInterpretation DecisionMaking EndpointDetermination Humans PatientDropouts PatientDropouts:statistics&numericaldata Pharmacology RiskAssessment RiskAssessment:methods Schizophrenia Schizophrenia:drugtherapy Software Statistical StatisticsasTopic %N 1 %P 56-9 %R 10.1038/clpt.2010.251 %T A concise display of multiple end points for benefit-risk assessment. %U http://www.ncbi.nlm.nih.gov/pubmed/21107317 %V 89 %X The assessment and representation of benefit-risk "balance" in pharmaceutical development have become increasingly important. Although the methodologies may vary considerably in complexity, most approaches to benefit-risk assessment require the simultaneous consideration of information pertaining to multiple end points for multiple treatments. However, the lengthy data tables and displays that are frequently used make this assessment difficult. Using an example from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, this note presents a conceptually simple visualization that facilitates understanding of information on multiple points. %@ 1532-6535; 0009-9236

@article{Levitan2011, abstract = {The assessment and representation of benefit-risk "balance" in pharmaceutical development have become increasingly important. Although the methodologies may vary considerably in complexity, most approaches to benefit-risk assessment require the simultaneous consideration of information pertaining to multiple end points for multiple treatments. However, the lengthy data tables and displays that are frequently used make this assessment difficult. Using an example from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, this note presents a conceptually simple visualization that facilitates understanding of information on multiple points.}, added-at = {2023-02-03T11:44:35.000+0100}, author = {Levitan, B}, biburl = {https://www.bibsonomy.org/bibtex/215356007aa353c43e5c831e1c8681226/jepcastel}, city = {Quantitative Safety Research, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Titusville, New Jersey, USA. blevitan@its.jnj.com}, doi = {10.1038/clpt.2010.251}, interhash = {3591ef537dbe93e7eb626ee003183708}, intrahash = {15356007aa353c43e5c831e1c8681226}, isbn = {1532-6535; 0009-9236}, issn = {1532-6535}, journal = {Clinical pharmacology and therapeutics}, keywords = {AntipsychoticAgents AntipsychoticAgents:adverseeffects AntipsychoticAgents:therapeuticuse Clinical Clinical:methods Clinical:trends Computer-Assisted ComputerGraphics DataInterpretation DecisionMaking EndpointDetermination Humans PatientDropouts PatientDropouts:statistics&numericaldata Pharmacology RiskAssessment RiskAssessment:methods Schizophrenia Schizophrenia:drugtherapy Software Statistical StatisticsasTopic}, month = {1}, note = {5920<m:linebreak></m:linebreak>JID: 0372741; 0 (Antipsychotic Agents); 2010/11/24 [aheadofprint]; ppublish;<m:linebreak></m:linebreak>Presentació de dades; Gràfics; Relació benefici/risc}, number = 1, pages = {56-9}, pmid = {21107317}, timestamp = {2023-02-03T11:44:35.000+0100}, title = {A concise display of multiple end points for benefit-risk assessment.}, url = {http://www.ncbi.nlm.nih.gov/pubmed/21107317}, volume = 89, year = 2011 }